← All trials
NCT05680558
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 8, 2021
- Primary completion
- Dec 14, 2025
- Completion date
- Jul 25, 2026
- First posted
- Jan 11, 2023
- Last posted
- May 30, 2023
- Enrollment
- 74
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Columbia UniversityLead sponsor
- Columbia UniversityOverall official - principal investigator
- Columbia UniversityReponsible party - principal investigator
- Columbia UniversitySponsor investigator
- MallinckrodtCollaborator
- Columbia UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.